Growth HormoneStrong Evidence

Tesamorelin

Also known as: Egrifta, TH9507, GHRH analog

Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.

Evidence

Strong

FDA status

FDA-approved

Source

Synthetic GHRH analog with trans-3-hexenoic acid modification

Overview

Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.

Mechanism of Action

Binds GHRH receptors on pituitary somatotrophs, stimulates pulsatile GH release, increases IGF-1, preferentially reduces visceral fat via GH-mediated lipolysis, minimal effect on subcutaneous fat.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Reduces visceral adipose tissue
  • Improves body composition
  • Lean body mass
  • Enhances GH and IGF-1 levels
  • Improves lipid profiles
  • Thinking and memory (small trials)

Researched for

Includes FDA-approved uses where marked; other items are research topics, not approved uses.

HIV-associated lipodystrophy (FDA approved)Visceral obesityAge-related GH declineMetabolic syndromeMild cognitive impairment (investigational)

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Tesamorelin isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Strong
Studies

Phase 3 trials, FDA approved for HIV lipodystrophy

Summary

FDA-approved (Egrifta) to reduce excess abdominal fat in adults with HIV and lipodystrophy, based on trials showing lower visceral fat. Other uses are off-label or investigational.

Safety Information

Potential Side Effects

  • •Injection site reactions
  • •Arthralgia
  • •Peripheral edema
  • •Muscle pain
  • •Elevated IGF-1
  • •Glucose intolerance

Contraindications

  • Active malignancy
  • Diabetic retinopathy
  • Pregnancy
  • Breastfeeding
  • Pituitary tumor

Interactions

  • ⚠May affect glucose metabolism
  • ⚠Monitor with diabetes medications

Quick Facts

CategoryGrowth Hormone
SourceSynthetic GHRH analog with trans-3-hexenoic acid modification
StatusFDA-approved (Egrifta) for excess abdominal fat in adults with HIV and lipodystrophy